Genome-wide CRISPR/Cas9 screening identifies CARHSP1 responsible for radiation resistance in glioblastoma

Guo-dong Zhu1,2,9, Jing Yu3,9, Zheng-yu Sun4,9, Yan Chen5, Hong-mei Zheng6, Mei-lan Lin2, Shi Ou-yang7, Guo-long Liu1, Jie-wen Zhang1 and Feng-min Shao1,8

© The Author(s) 2021

INTRODUCTION

Glioblastomas (GBM) is the most common primary malignant brain tumor, and radiotherapy plays a critical role in its therapeutic management. Unfortunately, the development of radioresistance is universal. Here, we identified calcium-regulated heat-stable protein 1 (CARHSP1) as a critical driver for radioresistance utilizing genome-wide CRISPR activation screening. This is a protein with a cold-shock domain (CSD)-containing that is highly similar to cold-shock proteins. CARHSP1 mRNA level was upregulated in irradiation-resistant GBM cells and knockdown of CARHSP1 sensitized GBM cells to radiotherapy. The high expression of CARHSP1 upon irradiation might mediate radioresistance by activating the inflammatory signaling pathway. More importantly, patients with high levels of CARHSP1 had poorer survival when treated with radiotherapy. Collectively, our findings suggested that targeting the CARHSP1/TNF-α inflammatory signaling activation induced by radiotherapy might directly affect radioresistance and present an attractive therapeutic target for GBM, particularly for patients with high levels of CARHSP1.

Calcium-regulated heat-stable protein 1 (CARHSP1), also known as CRHSP-24, has been identified as a cold-shock domain (CSD) protein family member, functions as a transcriptional or translational regulator [15, 16]. CARHSP1 contains a CSD, making it possible for it to bind to polypyrrimidine regions and regulate the stability of single-stranded RNA or DNA [17, 18]. Recently, it was found to be an mRNA stability enhancer for tumor necrosis factor-alpha (TNF-α), which is the central mediator of inflammation in macrophages, and several studies have demonstrated that CARHSP1 binds to the AU-rich element (ARE) of the TNF-α 3′-UTR through the CSD [19–21].

A number of traditional or novel drugs and natural products have shown their potent properties for radiosensitizers to block the inflammatory signaling pathway in cases of cancer [22, 23]. Seeking vulnerabilities of radioresistance targets in GBM is a promising strategy to improve the efficiency of radiotherapy. Through genome-scale gain-of-function screening, we found a new radioresistance target CARHSP1, which was amazingly overexpressed in radiotherapy-resistant GBM cells. In summary, we determined that the increased CARHSP1 level might play a radiotherapy protective role by signaling through the CARHSP1/TNF-α pathway.

First Affiliated Hospital of Chongqing Medical University, 400016 Chongqing, China. 2Department of Geriatrics, The First Affiliated Hospital of Guangzhou Medical University, 400016 Guangzhou, China. 3Department of Blood Transfusion, Wuhan No.1 Hospital/Wuhan Hospital of Traditional Chinese and Western Medicine, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, China. 4Department of Neurology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, 450003 Zhengzhou, Henan, China. 5Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University, 400016 Chongqing, China. 6Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology and Hubei Provincial Clinical Research Center for Breast Cancer, 430079 Wuhan, China. 7Department of Infection Disease, The Fifth Affiliated Hospital of Guangzhou Medical University, 510150 Guangzhou, China. 8Department of Nephrology, Henan Provincial Key Laboratory of Kidney Disease and Immunology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, 450003 Zhengzhou, Henan, China. 9email: zhangjiewen9900@126.com; fengminshao@126.com

Edited by G. Blandino

Received: 20 December 2020 Revised: 29 June 2021 Accepted: 1 July 2021
Published online: 21 July 2021
MATERIALS AND METHODS

Cell culture

The human glioblastoma U87 and U251 cell lines were obtained from Procell Life Science & Technology Co., Ltd (Wu Han, China) and were cultured in Dulbecco’s modified Eagle’s medium (DMEM, HyClone, SH30022.018), with 10% fetal bovine serum (FBS, Gibco) and 0.1% Penicillin/Streptomycin (P/S, TBD, P52004HY) in a humidified incubator with 5% CO₂ at 37°C.

Measurement of minimum radiation dose

Radiation of cells was performed at a dose rate of 0, 3, 6, 9, 12, 15, and 18 Gy/min with 6 MeV X-ray Irradiator using a Linear Accelerator, Elekta synergy. The growth of GBM cells was observed by an optical microscope (Nikon) and the OD value were then detected by CCK8 assay to determine the minimum lethal dose (MLD) of radiation.

Pooled genome-wide CRISPR screening

In this study, the Human CRISPR activation pooled library (Purchased from Addgene, #100000007, #89308) was used to identify genes responsible for radiation resistance in GBM cells. According to the CCK8 assay, the inhibition of cell growth was much more significant at a dose rate of 12 Gy/min (U87 cells) and 15 Gy/min (U251 cells). Therefore, 12 Gy/min (U87 cells) and 15 Gy/min (U251 cells) radiation doses were chosen in the following experiments. We first transfected the U87 and U251 cells with the activator plasmid MS2-P65-HSF1, selected with hygromycin B (YEASEN, 60225ES03). Then at least 1 × 10⁸ UB7 and U251 cells were transduced with pooled CRISPRa-Cas9 SAM human lentiviral library which contains 70,290 unique sgRNA sequences targeting 23,430 human genes (3 sgRNAs per gene) at a low MOI (~0.5) to ensure most cells received only one stably integrated RNA guide. The transduced cells were selected with blasticidin (MDBio, D0120601) for 15 days to generate a mutant cell pool, which was then subjected to massive parallel amplicon sequencing carried out by Novogene Technology (Beijing, China).

Genomic DNA extraction and sgRNA deep sequencing

The HiPure Tissue DNA Mini Kits (Magen) were used to extract genomic DNA. Amplification of the sgRNA sequences of each sample from the extracted genomic DNA using the CRISPRa-F: TCTTGGTGGAAAGGACGAA-CTGCG and CRISPRa-R:CTCTCTTCTCAAGCCTAGGATG primers. The thermo-cycling parameters were: 95°C for 60 s, followed by 35 cycles of (95°C for 10 s, 60°C for 10 s, and 72°C for 30 s) and a final extension at 72°C for 1 min. After the PCR products were electrophoresed, HiPure Gel Pure DNA Mini Kits were used for gel extraction. The pooled products were gel purified from a 2% E-gel EX (Life, Technologies) using the QiaQuick kit (Qiagen). The purified pooled library was then selected by agarose gel and subjected to massive parallel amplicon sequencing carried out by Novogene Technology (Beijing, China).

Screen enrichment analysis

The R software package (DESeq2) was applied to perform a statistical analysis of sequencing data. The Kyoto Encyclopedia of Genes and Genomes (KEGG) Orthology-Based Annotation System (KOBASE) 3.0 (http://kobas.cbi.pku.edu.cn/anno_iden.php) was used to identify significant biological pathways in the CRISPR library datasets.

TCGA data analysis

For 529 GBM samples in TCGA, mRNA seq and clinical data were retrieved from UCSC Xena (https://xenabrowser.net/datapages/) and convert FPKM data to TPM. Finally, 498 patients with mRNA expression data and prognosis information were divided into high expression group and low expression group according to the median (4.6978), and then Kaplan–Meier survival analysis and univariate Cox hazard analysis were performed. Finally, 139 patients in TCGA treated with radiotherapy were divided into high expression group and low expression group according to the median, and then Kaplan–Meier survival analyses were performed.

Lentiviral transduction

The pLenti-pLKO-KIA0895, pLenti-pLKO-STRAG6, pLenti-pLKO-FBLIM1, pLenti-pLKO-CARHSP1 and pLenti-piresEGFP-KIA0895, pLenti-piresEGFP-CARHSP1 plasmids were obtained from GENERAL BIOL. (Chuzhou, China). Lentiviruses were generated by co-transfecting the target plasmid and the packaging plasmid (pCMV-VS-VG, pMDLg pRRE, and 3 μg pRSV-Rev) into 293T cells using polyethyleneimine (PEI). U251 and U87 cells were seeded in 6-well plates and incubated with virus supernatant and observe the fluorescence at 48 h, after which they were screened with 5 μg/ml puromycin for 48 h. Puromycin-resistant cells were then used in downstream assays.

Cell proliferation assay

We detected the effect of different radiation doses on GBM cells transfected with STRA6, FBLIM1, KIA0895, CARHSP1 overexpression, and knockdown plasmids by CCK8 assay (Beyotime, Shanghai, China) according to the manufacturer’s instructions.

Quantitative reverse transcriptase PCR

The mRNA levels of STRA6, FBLIM1, KIA0895, and CARHSP1 (Supplementary Table S1 for primer sequences) were detected by real-time quantitative reverse transcriptase PCR (qRT-PCR). Total RNA was extracted using the total RNA Rapid Extraction Kit (BIOTEKE, RP1201) according to the manufacturer's instructions. The SYBR Green® Realtime PCR Master Mix (QPQK-201, Toyobo Co, Ltd, Osaka, Japan) was used for qRT-PCR assays. The data were analyzed on an Applied Biosystems 7900 Real-Time PCR System. The target genes were normalized to the mean β-actin expression.

Immunohistochemistry

Expression pattern and subcellular localization of CARHSP1 (Abcam, ab96677, 1:300) protein in clinical GBM tissues were detected by immunohistochemistry. Tumor specimens (Xi’an Alina Biotechnology Co., Ltd, GL803c) were scored in a semiquantitative manner due to the heterogeneity of the staining of the target proteins as described previously [24]. A final immunoreactivity scores (IRS) was obtained for each case by products of the percentages and the intensity scores.

Statistical analysis

Our data were expressed as means ± SD. Analyses were performed using IBM SPSS Statistics for Windows, version 20.0 (IBM Corp., Armonk, NY, USA). Comparisons between groups were analyzed through a one-way analysis of variance (ANOVA). P-values less than 0.05 were considered statistically significant.

RESULTS

A whole-genome CRISPR screen identifies mediators of irradiation resistance

In this study, the human CRISPR activation pooled library, which included 70,290 sgRNAs targeting 23,430 protein-coding genes in the human genome was used to identify genes responsible for irradiation resistance in GBM cells. Figure 1A displayed a schematic of irradiation-resistant GBM cells enrichment for high-throughput sequencing analysis. To measure the minimum radiation dose of GBM cells to radiation, we treated human U251 and U87 cell lines with different doses of gamma radiation. The CCK8 assay indicated a dose-dependent growth inhibition by radiation. According to the result (Fig. 1B), few U87 cells survived at day 6 following treatment with 12 Gy/min irradiation, and all cells died with 15 Gy/min radiation. Therefore, 12 Gy/min (U87 cells) and 15 Gy/min (U251 cells) radiation doses were chosen in the following experiments.

Enriched genes in irradiation-resistant GBM cells

The mutant cell pool was treated with 12 Gy/min (U87 cells) or 15 Gy/min (U251 cells) radiotherapy for three rounds, respectively, and the surviving cells were enriched (Supplementary Fig. S1). The survival resistant cells were cultured and collected to extract DNA and PCR amplification of the 209-bp sgRNA region was used for high-throughput sequencing to calculate the sgRNAs coverage in the cells. The genes with the top 10% of sgRNA abundance in U87...
and U251 cells (Supplementary Table S2) were intersected and the 86 genes were then used for Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis to determine the processes that mediated irradiation resistance. Figure 2A showed significant enrichment of 15 pathways, including metabolic pathways, Hippo signaling pathway, Protein processing in the endoplasmic reticulum, MAPK signaling pathway, and so on. We further analyzed genes with sgRNA diversity >3 (Supplementary Table S2) in U87 and U251 cells and 94 genes were enriched (Fig. 2B). The result showed these genes were enriched in the FoxO signaling pathway, Pathways in cancer, mTOR signaling pathway, PI3K-Akt signaling pathway, etc (Fig. 2B). There are 15 genes both with top 10% of sgRNA abundance and sgRNA diversity greater than 3 (freq > 3) in U251 and U87 cells. Finally, the TCGA data were
combined to further analyze the 15 genes, 4 of which affect the prognosis of GBM ($P < 0.01$).

We analyzed a total of 498 patients with mRNA expression data and prognosis information, then the samples were divided into high expression group and low expression group according to the median. Kaplan–Meier survival analysis and univariate Cox hazard analysis were performed. The Kaplan–Meier analysis indicated that GBM patients with high expression of CARHSP1, KIAA0895, FBMIL1, and STRA6 exhibited worse overall survival. CARHSP1, FBMIL1, and STRA6 mRNA expression were selectively upregulated in GBM compared with the Normal (GEPIA).
Knockdown of the candidate genes sensitized GBM cells to irradiation

CARHSP1 [21] contains a cold-shock domain with two RNA binding motifs, which preferentially bind polypyrimidine regions of single-stranded RNA and DNA and regulate ribosomal translation, mRNA degradation, and the rate of transcription termination. We hypothesized high levels of CARHSP1, KIAA0895, FBML1, and STRA6 may promote tumor progression. Thus, we investigated whether inhibition of these genes sensitized GBM cells to irradiation treatment. Cell proliferation assay showed that downregulation of CARHSP1, KIAA0895, FBML1, and STRA6 could significantly inhibit U87 and U251 cell proliferation when treated with different doses of irradiation ($P < 0.05$, $P < 0.01$) (Fig. 4A). The time-course cell proliferation experiments with 15 or 12 Gy/min irradiation also showed that knockdown of candidate genes could significantly increase the sensitivity of GBM cells to radiotherapy ($P < 0.05$, $P < 0.01$, $P < 0.001$) (Fig. 4B). Taken together, the result demonstrated that inhibition of CARHSP1, KIAA0895, FBML1, and STRA6 sensitized GBM cells to irradiation treatment.

The candidate genes upregulated in irradiation-resistant GBM cells

Furthermore, the U251 and U87 cells were treated with a minimal lethal dose of radiation. After three rounds of treatment, the irradiation-resistant cells are enriched. Then qPCR was applied to determine the expression levels of CARHSP1, KIAA0895, FBML1, and STRA6 mRNAs in U251 and U87 cells and irradiation-resistant GBM cells. As shown in Fig. 5(A-B), the expression levels of CARHSP1, FBML1, and STRA6 mRNAs were significantly higher in irradiation-resistant GBM cells than that in wild-type GBM cells ($P < 0.05$). These 3 genes (CARHSP1, FBML1, and STRA6) might be the potential genes for irradiation resistance, while KIAA0895 showed an uncertain relationship with irradiation resistance.

CARHSP1 facilitates irradiation resistance through promoting TNF-α in vitro

It was reported that CARHSP1 was specifically interacting with the 3′UTR of TNF-α and knockdown of CARHSP1 inhibited TNF-α protein production in lipopolysaccharide (LPS)-stimulated cells and reduced the level of TNF-α mRNA in both resting and LPS-stimulated cells [21]. Correlation analysis of the TCGA data showed that CARHSP1 mRNA level is positively correlated with TNF-α at $P = 0.034$ (Fig. 6A), which was proved in CARHSP1 knockdown and overexpression GBM cells by qPCR ($P < 0.05$) (Fig. 6B). We deduced high level of CARHSP1 could lead to irradiation resistance by promoting the expression of TNF-α. Therefore, the CCK8 assay was used to prove whether the TNF-α level could influence the sensitivity of GBM cells to radiotherapy. The result showed TNF-α inhibition could significantly suppress U251 and U87 cell proliferation when treated with different doses of irradiation ($P < 0.01$), while TNF-α stimulator promoted GBM cell proliferation under radiotherapy treatment (Fig. 6C).

CARHSP1 mRNA levels correlate with survival in GBM patients with radiotherapy

The expression levels of CARHSP1 protein in GBM and adjacent normal brain tissues were examined by immunohistochemistry analysis. As a result, the positive, moderate or weak
immunostaining of CARHSP1 protein was shown in GBM tissues and the weak immunostaining was shown in adjacent normal brain tissues (Fig. 7C). Statistically, the IRS value of CARHSP1 protein in GBM tissues was significantly higher than that in adjacent normal brain tissues (IRS, GBM, 7.6 ± 3.0 vs. benign, 4.8 ± 1.8, \( P < 0.05 \), Fig. 7B). In addition, high expression of CARHSP1 protein was associated with age (\( P = 0 \)), pathological grade (\( P = 0 \)) (Fig. 7D) and recurred (\( P = 0.0009 \)) (Supplementary Table S3). The 139 irradiation-treated patients (Supplementary Table S4) were divided into CARHSP1 low and high expression groups according to the IRS value.

**Fig. 4** Knockdown of the candidate genes sensitized GBM cells to radiotherapy. A U87 and U251 cell lines with single gene knockdown were treated with 0, 6, 12, and 18 Gy/min irradiation, and cell viability was measured using a CCK8 assay. B The U87 and U251 cell lines were transfected with CARHSP1, KIAA0895, FBML1, and STRA6 knockdown plasmid. Time-course cell proliferation experiments (4 h, 24, 48 h, 72 h) under 12 or 15 Gy/min irradiation were detected by CCK8. Data were represented as means ± SD of three independent experiments.

**Fig. 5** Quantitative real-time PCR analysis for mRNA levels of the candidate genes in wild-type GBM cells and irradiation-resistant GBM cells. A CARHSP1 mRNA level in U87 cells was detected, the irradiation-resistant cells of U87 cells were enriched by treating with 12 Gy radiation for three rounds. B CARHSP1 mRNA level in U251 cells was detected, the irradiation-resistant cells of U251 cells were enriched by treating with 15 Gy radiation for three rounds. Data were represented as means ± SD of three independent experiments.
to the same threshold as the total survival analysis (4.6978) and then the survival analysis was conducted. Surprisingly, we found that irradiation-treated patients with high CARHSP1 mRNA levels had significantly poorer survival compared with patients with low CARHSP1 levels (Fig. 7E, \( P = 0.0177 \), log-rank test). These results suggest that CARHSP1 is a poor prognostic marker in GBM, more importantly, high CARHSP1 mRNA identifies patients less responsive to radiotherapy and could be prognostic of overall survival.

**DISCUSSION**

Glioblastoma (GBM) is one of the most aggressive brain tumors. Surgery followed by radiotherapy is the standard therapeutic regimen for GBM [9]. Upon treatment by radiation, the primary response of GBM cells is proliferation arrest and the arrested cells then undergo premature senescence within 4–8 days after irradiation [25]. Although the treatments could prolong survival of GBM patients, almost all patients eventually develop resistance. Therefore, there is a critical need to understand how radioresistance is acquired. The previous study [2, 26] has shown that mesenchymal signature, CD44 expression, NF-κB activation and induction of ER stress signaling correlated with poor radiation response and shorter survival in patients with GBM. There is still an urgent need to discover new therapeutic targets that can enhance the radiotherapy sensitivity of GBM.

The genome-wide CRISPR/Cas9 screening enables researchers to identify genes contributing to a specific phenotype. In this study, we adopted the transcriptional activation screening strategy using the SAM2 library to identify determinate genes that are essential for radioresistance in GBM as previously described [27, 28]. Here, we showed that the gain-of-function of CARHSP1, KIAA0895, FBML1, and STRA6 was highly associated with radioresistance in GBM. Further study showed that inhibition of TNF-α could signiﬁcantly suppress GBM cells proliferation, while TNF-α stimulator promoted GBM cell proliferation under radiotherapy treatment. Mechanistically, a gain of CARHSP1 might facilitate radioresistance through promoting TNFα.

TNF-α is a pleiotropic cytokine and a central mediator of inflammation, and chronic inflammation mediated by TNF-α is also associated with tumor progression [38, 39]. It was proved that
knockdown of CARHSP1 inhibits TNF-α protein production in LPS-stimulated cells and reduces the level of TNF-α mRNA in both resting and LPS-stimulated cells [21]. Moreover, the TNF-α/NF-κB pathways were significantly activated following radiotherapy(10,10),(990,991) which indicated the activation of inflammatory genes upon radiation [40]. Thus, we concluded that the high expression of CARHSP1 upon radiation might mediate radioresistance by activating the TNF-α/NF-κB pathway. More importantly, high CARHSP1 levels were correlated with poorer survival in irradiation-treated GBM patients according to the TCGA database. Targeting the CARHSP1/TNF-α inflammatory signaling activation induced by radiotherapy might directly affect radioresistance and presents an attractive therapeutic target for GBM.

Collectively, these findings suggested that CARHSP1 contributes to in vitro resistance to radiotherapy in GBM cancer cells. We showed that patients with high levels of CARHSP1 had poorer survival when treated with radiotherapy. Targeting the CARHSP1/TNF-α inflammatory signaling activation induced by radiotherapy might directly affect radioresistance and presents an attractive therapeutic target for GBM, particularly for patients with high levels of CARHSP1.

Fig. 7 High CARHSP1 levels correlate with poorer survival in irradiation-treated GBM patients. A Overall staining of tissue microarray. B The IRS value of CARHSP1 protein in GBM tissues was significantly higher than that in adjacent normal brain tissues. C The positive, moderate, or weak immunostaining of CARHSP1 protein was shown in GBM tissues and the weak immunostaining of CARHSP1 protein in adjacent normal brain tissues. D High CARHSP1 expression was significantly associated with pathological grade in TCGA data. E Overall survival for irradiation-treated GBM patients (a total of 139 patients) showed high levels of CARHSP1 correlate with poorer survival.

REFERENCES
1. Ramirez YP, Weatherbee JL, Wheelhouse RT, Ross AH. Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals 2013;6:1475–506.
2. Daday DT, Kapoor V, Khudanpur A, Thotala D, Hallahan DE. PERK regulates glioblastoma sensitivity to ER stress while promoting radiation resistance. Mol Cancer Res. 2018;16:1447–53.
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.
4. Todorova PK, Fletcher Sananikone E, Mukherjee B, Kollipara R, Vemireddy V, Xie XJ, et al. Radiation-induced DNA damage cooperates with heterozygosity of TP53 and PTEN to generate high grade gliomas. Cancer Res. 2019;79:3749–61.
5. Koh PK, Faivre-Finn C, Blackhall FH, De Ruyscher D. Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy. Cancer Treat Rev. 2012;38:626–640.
6. Johnson AE, Mazor T, Hong C, Barnes M, Ahara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343:189–93.
7. Kim H, Zheng S, Amini SS, Virk SM, Mikkelsen T, Brat DJ, et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015;25:316–327.
Park SH, Audia A, Shi J, Lu S, Bemstok J, Pavlyukov MS, et al. Phenotypic plasticity of invasive edge glioma stem-like cells in response to ionizing radiation. Cell Rep. 2019;26:1893–905.

Zhang L, Cheng F, Wei Y, Zhang L, Guo D, Wang B, et al. Inhibition of TAZ contributes radiation-induced senescence and growth arrest in glioma cells. Oncogene 2019;40:3815.

Kim WY, Youn H, Kang C, Yoon B. Inflammation-mediated radiosensitivity is mediated by ROS-dependent inactivation of protein phosphatase 1 in non-small cell lung cancer cells. Apoptosis. 2015;20:1242–52.

Wang L, Yang H, Palmos SL, Ney G, Detzler TA, Coleman D. ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates radiosensitivity in pancreatic cancer cells. Cancer Res. 2014;74:1778–86.

Maraman C, Gravina GL, Zani BM, Papov VM, Fratticci A, Cerasani M, et al. Hypoxia sustains globlastoma radiosensitivity through ERK1/2-DNA-PKcs/HIF-1alpha functional interplay. Int J Oncol. 2014;44:2121–31.

Multhoff G, Hudson AL, Back M, Eade T, Diakos C. Radiation, inflammation, and immune responses in cancer. Front Oncol. 2012;2:58.

Roughton K, Andresson U, Blomgren K, Kalm M. Lipopolysaccharide-induced inflammation aggravates irradiation-induced injury to the young mouse brain. Dev Neurosci. 2013;35:406–15.

Lindquist JA, Brandt S, Bernhardt A, Zhu C, Mertens PR. The role of cold shock domain proteins in inflammatory diseases. J Mol Med. 2014;92:207–16.

Li XY, Kong D, Chen H, Liu S, Hu H, Wu T, et al. mif-155 acts as an anti-inflammatory factor in atherosclerosis-associated foam cell formation by repressing calcium-regulated heat stable protein 1. Sci Rep. 2016;6:21789.

Schafer C, Steffen H, Kryzwki KJ, Göke B, Gribblewski GE. CRHSP-24 phosphorlylation is regulated by multiple signaling pathways in pancreatic acinar cells. Am J Physiol Gastrointest Liver Physiol. 2003;285:G726–734.

Hou H, Wang F, Zhang W, Wang D, Li X, Bartlam M, et al. Structure-functional analyses of CRHSP-24 plasticity and dynamics in oxidative stress response. J Biol Chem. 2011;286:3623–35.

Yan G, You B, Chen SP, Liao JK, Sun J. Tumor necrosis factor-alpha downregulates α1-antitrypsin functional interplay. Int J Oncol. 2014;43:1432–7.

Li F, Sethi G. Targeting transcription factor NF-κB to overcome chemoresistance of mesenchymal glioblastoma initiating cells correlates with patient outcome and is associated with activation of inflammatory program. Oncotarget. 2017;8:17346–50.

AUTHOR CONTRIBUTIONS
All the authors contributed extensively to the work presented in this paper. F-mS, J-wZ, and G-dz: participated in study design and coordination, analysis and interpretation of data, material support for obtained funding, and supervised the study. G-dz, Ji, and Z-yS: performed most of the experiments and statistical analysis and drafted the manuscript. YC, H-MZ, and G-dL: participated in data analysis and paper modification. M-WL and O-yC: participate in the experiment. All authors read and approved the final manuscript.

FUNDING
This work was supported by grants from Guangdong Planned Project of Science and Technology (2014A020221001), Guangzhou Planned Project of Science and Technology (20201001030, 201704020105).

ETHICS STATEMENT
Not applicable.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-021-04000-3.

Correspondence and requests for materials should be addressed to J-wZ. or F-mS.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.